Kendra Adams - 18 Sep 2023 Form 3 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role: Chief Financial Officer
Signature: /s/ Jolie M. Siegel, Attorney-in-Fact
Issuer symbol: CCCC
Transactions as of: 18 Sep 2023
Net transactions value: $0
Form type: 3
Filing time: 19 Sep 2023, 19:20:09 UTC
Next filing: 15 Feb 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	CCCC	Common Stock						21,640	18 Sep 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	CCCC	Stock Option (Right to Buy)							18 Sep 2023	Common Stock	57,375	$19.00	Direct	F2
holding	CCCC	Stock Option (Right to Buy)							18 Sep 2023	Common Stock	45,000	$22.71	Direct	F3
holding	CCCC	Stock Option (Right to Buy)							18 Sep 2023	Common Stock	75,000	$5.67	Direct	F4
holding	CCCC	Performance Restricted Stock Units							18 Sep 2023	Common Stock	16,500		Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes a grant of 15,000 restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs vest in four equal annual installments, with the first installment vesting on February 13, 2024, subject to the Reporting Person's continued service on each vesting date.
F2	Represents underlying unexercised stock options that were granted on November 9, 2020. The terms of the original grant provide that 25% of this option vested and became exercisable on November 9, 2021, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service on each vesting date.
F3	This option vests and becomes exercisable in sixteen equal quarterly installments, with the first installment vested on May 14, 2022, subject to the Reporting Person's continued service on each vesting date.
F4	This option vests and becomes exercisable in sixteen equal quarterly installments, with the first installment vested on May 13, 2023, subject to the Reporting Person's continued service on each vesting date.
F5	Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones.

Remarks:

Exhibit 24 - Power of Attorney